PODD Insulet Corporation

INSULET INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Insulet Corporation for Possible Securities Fraud - PODD

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Insulet Corporation (NasdaqGS: PODD).

On May 6, 2013, Insulet announced the successful launch of its new Eros system, touting positive customer feedback, the transition of all new customers to the system and a resulting growth in both United States and overseas markets. However, in truth, the company experienced significant quality problems with Eros throughout 2013 and 2014. On January 7, 2015 and again on April 30, 2015, the Company revealed that revenues were much lower than forecasted, due in part to a myriad of issues with the Eros system. Further, on June 5, 2015, the U.S. FDA issued a letter to the Company regarding defective lots of Eros that had been manufactured and shipped between 2013 and 2014 resulting in the Company recalling over 40,000 boxes of the product.

Thereafter, Insulet and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws. On March 17, 2017, the Court denied Insulet’s motion to dismiss the securities class action complaint.

KSF’s investigation is focusing on whether Insulet and/or its officers and directors violated state or federal securities laws.

If you are an Insulet shareholder and have suffered losses, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]).

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
27/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Insulet Corporation

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Moody's Ratings upgrades Insulet's CFR to Ba3; outlook remains positiv...

Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to Ba3 from B1 and Probability of Default Rating ("PDR") to Ba3-PD from B1-PD. Concurrently, we affirmed the Ba2 rating on Insulet's senior secured term loan and assigned a Ba2 rating to Insulet's new ...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Insulet Corporation: Update to credit analysis following CFR upgrade

Our credit view of this issuer reflects its strong competitive position, but single product line focus.

Moody's Ratings upgrades Insulet's CFR to B1; outlook remains positive

Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to B1 from B2 and Probability of Default Rating ("PDR") to B1-PD from B2-PD. Concurrently, we affirmed the Ba2 ratings on Insulet's senior secured credit facilities, including the senior secured term l...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch